Form 4: NEOGENOMICS COO Stone Boosts Equity Holdings

Neogenomics President & COO Warren Stone reported significant new equity grants, including stock options and restricted stock units, alongside existing holdings.

Summary

• Warren Stone, President & Chief Operating Officer of Neogenomics Inc. (NEO), reported new equity grants on March 1, 2026.
• These new grants include 253,378 stock options with an exercise price of $10.81, vesting ratably over three years from the grant date and expiring on March 1, 2036.
• Additionally, 152,594 restricted stock units (RSUs) were granted on March 1, 2026, also vesting ratably over three years.
• Stone's total beneficial ownership includes 147,714 shares of common stock directly.
• His derivative holdings comprise a substantial number of stock options (783,564 shares), restricted stock units (356,839 units), and performance stock units (64,442 units at target) from various grants dating back to December 2022, with varying vesting schedules and performance criteria.
• A promotion to President & Chief Operating Officer on April 1, 2025, resulted in modified vesting schedules for certain previously granted options and RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive incentive alignment and retention efforts, particularly with performance-based awards and premium-priced options, which suggest confidence in future growth.

Positives

• Significant new equity grants (253,378 stock options and 152,594 RSUs) demonstrate continued commitment and incentive for the COO.
• Performance Stock Units (PSUs) are tied to share growth and revenue growth goals, aligning management incentives with shareholder value and company performance.
• The premium-price stock options (e.g., $10.81 and $13.05) indicate a belief in future stock price appreciation beyond the grant date closing price.
• The modification of vesting schedules for some grants following Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, suggests a strategic move to retain and incentivize key leadership.

Future Outlook

The performance stock units granted to Mr. Stone are tied to the achievement of certain share growth goals based on the weighted average price of the Company's common stock and, for some grants, cumulative fiscal year revenue goals, indicating a forward-looking incentive structure for management.

Industry Context

StockSavvy.ai notes that equity grants, particularly those with performance-based vesting conditions, are a standard practice in the biotechnology and diagnostics industry to align executive incentives with long-term shareholder value creation. The mix of stock options, restricted stock units, and performance stock units reflects a comprehensive compensation strategy aimed at both retention and performance.

Comparison to Industry Standards

• The use of premium-price stock options, such as those granted with exercise prices of $10.81 and $13.05 (110% of closing price), is a less common but increasingly adopted practice in high-growth sectors like diagnostics, seen in companies like Guardant Health (GH) or Exact Sciences (EXAS), to ensure executives are incentivized only when the stock significantly outperforms.
• Performance Stock Units (PSUs) tied to both share price growth and revenue growth, as seen in Mr. Stone's grants, are a robust compensation mechanism, comparable to practices at leading life sciences companies such as Illumina (ILMN) or Thermo Fisher Scientific (TMO), which often link executive pay to specific financial and operational milestones.
• The multi-year vesting schedules (e.g., 3-4 years) for stock options and RSUs are consistent with industry best practices for executive retention, similar to those observed at peer companies like Invitae (NVTA) or Natera (NTRA), ensuring long-term commitment from key personnel.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grants, particularly performance-based units, align executive incentives with shareholder value creation through share price and revenue growth. Premium-priced options suggest management confidence in future stock appreciation.
• Employees: The promotion of Mr. Stone to President & Chief Operating Officer indicates internal career progression opportunities and a stable leadership structure.

Next Steps

• Continued vesting of various stock options, restricted stock units, and performance stock units over their respective schedules.
• Achievement of share growth and revenue growth goals for performance stock units to maximize potential payouts.

Key Dates

Recommendation

This Form 4 primarily details routine equity grants and existing beneficial ownership for a key executive. While the grants align management incentives with company performance and suggest confidence, they do not present new fundamental information that would warrant a change in investment thesis. The promotion of Mr. Stone is a positive for leadership stability, but the filing itself is a standard disclosure of compensation.

Keywords

NEOGENOMICS, NEO, Warren Stone, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Grants, Executive Compensation, Beneficial Ownership